No products in the cart.
Diagnostic hapten-carrier conjugates BSA-Sodium valproate (VPA), OVA-Sodium valproate (VPA), KLH-Sodium valproate (VPA) for EpilepsyVPAdetection in Competitive immunoassay validation (Competitive ELISA), Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
Cat:GMP-SMT-VPA-Ag-Ab
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Valproate (VPA) and its valproic acid, sodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.Genemedi produces core diagnostic ingredients for test of Epilepsy and related syndrome.
GeneMedi offers Diagnostic hapten-carrier conjugates BSA-Sodium valproate (VPA), OVA-Sodium valproate (VPA), KLH-Sodium valproate (VPA) for Epilepsy VPA detection in Competitive immunoassay validation (Competitive ELISA), Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Epilepsy test are suitable for in functional ELISA, and other immunoassays in dignostics.
Product Description
|
Cat No.
|
GMP-SMT-VPA-Ag-Ab
|
|
Product Name
|
BSA-Sodium valproate (VPA) / OVA-Sodium valproate (VPA)
|
|
Expression platform
|
Synthetic
|
|
Bioactivity validation
|
Sodium valproate (VPA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in VPA level test of Epilepsy (toxicity) and related syndrome evaluation
|
|
Products description
|
Competitive immunoassay-validated hapten-carrier conjugates BSA-Sodium valproate (VPA) / OVA-Sodium valproate (VPA) is Synthetic.
|
|
Purity
|
|
|
Application
|
Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
|
|
Formulation
|
Lyophilized from sterile PBS, PH 7.4
|
|
Storage
|
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
|
|
Cat No.
|
GMP-SMT-VPA-Ag-Ab
|
|
Product Name
|
Anti-human Sodium valproate (VPA) mouse monoclonal antibody (mAb)
|
|
Expression platform
|
Hybridoma
|
|
Isotypes
|
Mouse IgG
|
|
Bioactivity validation
|
Sodium valproate (VPA) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Sodium valproate (VPA) antibodies in VPA level test of Epilepsy (toxicity) and related syndrome evaluation.
|
|
Tag
|
mFc
|
|
Products description
|
Anti-human Sodium valproate (VPA) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
|
|
Specics
|
mouse
|
|
Purity
|
Purity: ≥95% （SDS-PAGE）
|
|
Application
|
Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
|
|
Formulation
|
Lyophilized from sterile PBS, PH 7.4
|
|
Storage
|
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
|
Previous slide
Next slide
Diagnostic antibodies and antigens for Epilepsy-related valproate (VPA) toxicity testing: Sodium valproate (VPA)
Valproate is a commonly used antiepileptic drug for the treatment of epilepsy and seizures. It is safe for use in both adults and children more than three years of age. Valproate toxicity can occur both accidentally and intentionally. Acute valproate overdose usually presents with CNS depression/encephalopathy, electrolyte abnormalities such as hypernatremia, elevated transaminase levels, hyperammonemia, and hepatoxicity. In patients with a severe overdose of valproate, patients can present with hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related hyperammonemic encephalopathy which may progress to coma and death. GENEMEDI developed the Gastrin-17 (G-17) antigens and antibodies for the diagnosis of valproate toxicity based on ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
